ATAI Launches Subsidiary Focused On Active Ingredient In Hallucinogenic Brews

Psychedelics and biotech company ATAI Life Sciences announced Wednesday the launch of Viridia Life Sciences.

This wholly-owned subsidiary will be dedicated to the study and production of the DMT molecule (N,N-Dimethyltryptamine).

DMT is a psychoactive alkaloid present in Ayahuasca, a hallucinogenic brew traditionally used by indigenous communities in South America. The compound has gained attention in recent decades in North America for its ability to induce psychedelic experiences with a rapid onset and shorter duration than other psychedelic drugs.

While a typical LSD or psilocybin experience can last upwards of six hours, DMT’s hallucinogenic effects can reach a peak and extinguish in less than 15 minutes. 

Exploring Alternative Routes Of Administration

Most common applications of …

Full story available on Benzinga.com

More ATAI Launches Subsidiary Focused On Active Ingredient In Hallucinogenic Brews